Literature DB >> 14705145

Retinoic acid-induced neuritogenesis of human neuroblastoma SH-SY5Y cells is ERK independent and PKC dependent.

Mariarosaria Miloso1, Daniela Villa1, Marco Crimi2, Stefania Galbiati1, Elisabetta Donzelli1, Gabriella Nicolini1, Giovanni Tredici1.   

Abstract

Retinoic acid (RA), an active metabolite of vitamin A, is a natural morphogen involved in development and differentiation of the nervous system. To elucidate signaling mechanisms involved in RA-induced neuritogenesis, we used human neuroblastoma SH-SY5Y cells, an established in vitro model for studying RA action, to examine the role of extracellular signal-regulated kinase (ERK) 1 and 2 in RA-induced neuritogenesis and cell survival. From immunoblotting experiments, we observed that RA induced delayed but persistent ERK1 and ERK2 phosphorylation (until 96 hr) that was reduced significantly by the specific mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126. For the subsequent studies we chose 24 hr as the reference time. Inhibition of ERK activation did not affect RA-induced neuritogenesis (percentage of neurite-bearing cells and neurite length) but significantly reduced cell survival. In addition, we analyzed the signaling pathway that mediates ERK activation. Our results suggest that RA-induced ERK phosphorylation does not follow the classic Raf kinase-dependent pathway. Protein kinase C (PKC) and phosphatidylinositol 3-kinase (PI 3-K) are possible alternative kinases involved in the ERK signaling pathway. In fact, in the presence of the specific PKC inhibitor GF 109203X, or the specific PI 3-K inhibitor wortmannin, we observed a significant dose-dependent reduction in ERK phosphorylation. RA-induced neuritogenesis and cell survival were reduced by GF 109203X in a concentration-dependent manner. These results suggest that rather than ERK1 and ERK2, it is PKC that plays an important role during early phases of RA-induced neuritogenesis. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14705145     DOI: 10.1002/jnr.10848

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  30 in total

1.  Identification of the RA response element and transcriptional silencer in human alphaCaMKII promoter.

Authors:  Lu Wang; Jing Bai; Yinghe Hu
Journal:  Mol Biol Rep       Date:  2007-01-13       Impact factor: 2.316

2.  Abeta peptide toxicity is reduced after treatments decreasing phosphatidylethanolamine content in differentiated neuroblastoma cells.

Authors:  Emanuela Cazzaniga; Alessandra Bulbarelli; Elena Lonati; Antonina Orlando; Francesca Re; Maria Gregori; Massimo Masserini
Journal:  Neurochem Res       Date:  2011-02-03       Impact factor: 3.996

3.  MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets.

Authors:  Minh T N Le; Huangming Xie; Beiyan Zhou; Poh Hui Chia; Pamela Rizk; Moonkyoung Um; Gerald Udolph; Henry Yang; Bing Lim; Harvey F Lodish
Journal:  Mol Cell Biol       Date:  2009-07-27       Impact factor: 4.272

4.  Tripeptidyl Peptidase II Mediates Levels of Nuclear Phosphorylated ERK1 and ERK2.

Authors:  Anne Wiemhoefer; Anita Stargardt; Wouter A van der Linden; Maria C Renner; Ronald E van Kesteren; Jan Stap; Marcel A Raspe; Birgitta Tomkinson; Helmut W Kessels; Huib Ovaa; Herman S Overkleeft; Bogdan Florea; Eric A Reits
Journal:  Mol Cell Proteomics       Date:  2015-06-03       Impact factor: 5.911

5.  Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2015-05-05       Impact factor: 6.261

6.  TIRFM and pH-sensitive GFP-probes to evaluate neurotransmitter vesicle dynamics in SH-SY5Y neuroblastoma cells: cell imaging and data analysis.

Authors:  Federica Daniele; Eliana S Di Cairano; Stefania Moretti; Giovanni Piccoli; Carla Perego
Journal:  J Vis Exp       Date:  2015-01-29       Impact factor: 1.355

7.  In vitro optimization of retinoic acid-induced neuritogenesis and TH endogenous expression in human SH-SY5Y neuroblastoma cells by the antioxidant Trolox.

Authors:  Mario Luiz Conte da Frota Junior; André Simões Pires; Fares Zeidán-Chuliá; Ivi Juliana Bristot; Fernanda M Lopes; Matheus Augusto de Bittencourt Pasquali; Alfeu Zanotto-Filho; Guilherme Antônio Behr; Fabio Klamt; Daniel Pens Gelain; José Cláudio Fonseca Moreira
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

8.  UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.

Authors:  Evan F Garner; Laura L Stafman; Adele P Williams; Jamie M Aye; Caroline Goolsby; Venkatram R Atigadda; Blake P Moore; Li Nan; Jerry E Stewart; Anita B Hjelmeland; Gregory K Friedman; Elizabeth A Beierle
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

9.  Extracellular matrix rigidity modulates neuroblastoma cell differentiation and N-myc expression.

Authors:  Wilbur A Lam; Lizhi Cao; Vaibhavi Umesh; Albert J Keung; Shamik Sen; Sanjay Kumar
Journal:  Mol Cancer       Date:  2010-02-10       Impact factor: 27.401

10.  Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Abeta42 reduces their differentiation potential.

Authors:  Markus Uhrig; Peter Brechlin; Olaf Jahn; Yuri Knyazev; Annette Weninger; Laura Busia; Kamran Honarnejad; Markus Otto; Tobias Hartmann
Journal:  BMC Med       Date:  2008-12-16       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.